Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Panadol Extra Soluble Tablets

Active Ingredient:
paracetamol, caffeine
Haleon UK Trading Limited See contact details
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 12 Sep 2023
1. Name of the medicinal product

Panadol Extra Soluble Tablets

2. Qualitative and quantitative composition

Each tablet contains Paracetamol Ph.Eur. 500.0 mg and Caffeine Ph.Eur. 65.0 mg.

3. Pharmaceutical form

Effervescent tablet.

4. Clinical particulars
4.1 Therapeutic indications

Panadol Extra is a mild analgesic and antipyretic formulated to give extra pain relief. The soluble tablets are recommended for the treatment of most painful and febrile conditions, for example, headache including migraine, backache, toothache, colds and influenza, sore throat, rheumatic pain and dysmenorrhoea.

4.2 Posology and method of administration

Panadol Extra should be dissolved in at least half a tumblerful of water.

Adults (including the elderly) and children aged 16 years and over:

Two tablets up to four times daily.

Do not exceed 8 tablets in 24 hours.

Children aged 12-15 years:

One tablet up to four times daily.

Do not exceed 4 tablets in 24 hours.

Not recommended for children under 12 years.

Do not take more frequently than every 4 hours.

Do not take for longer than three days without consulting your doctor.

Method of Administration

Panadol Extra Soluble Tablets are for oral administration only.

4.3 Contraindications

Hypersensitivity to paracetamol, caffeine or any of the other constituents.

4.4 Special warnings and precautions for use

Do not exceed the stated dose.

Contains paracetamol. Do not use with any other paracetamol containing products. The concomitant use with other products containing paracetamol may lead to an overdose.

Paracetamol overdose may cause liver failure which may require liver transplant or lead to death.

Care is advised in the administration of paracetamol to patients with renal or hepatic impairment. The hazard of overdose is greater in those with non-cirrhotic alcoholic liver disease.

Caution should be exercised in patients with glutathione depleted states, as the use of paracetamol may increase the risk of metabolic acidosis (see section 4.9).

Excessive intake of caffeine (e.g. coffee, tea and some canned drinks) should be avoided while taking this product.

This medicinal product contains 854 mg sodium per dose (2 tablets) equivalent to 42.7% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

Each tablet contains sorbitol powder (E 420) at 50 mg per tablet. Patients with rare hereditary problems of fructose intolerance should not take this medicine.

If symptoms persist, medical advice must be sought.

Keep out of the sight and reach of children.

Pack Label:

Talk to a doctor at once if you take too much of this medicine, even if you feel well. Do not take anything else containing paracetamol while taking this medicine.

Patient Information Leaflet:

Talk to a doctor at once if you take too much of this medicine even if you feel well. This is because too much paracetamol can cause delayed, serious liver damage.

4.5 Interaction with other medicinal products and other forms of interaction

The speed of absorption of paracetamol may be increased by metoclopramide or domperidone and absorption reduced by colestyramine. The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular daily use of paracetamol with increased risk of bleeding; occasional doses have no significant effect. Caffeine may increase clearance of lithium. Concomitant use is therefore not recommended.

4.6 Pregnancy and lactation

Paracetamol-caffeine is not recommended for use during pregnancy due to the possible increased risk of lower birth weight and spontaneous abortion associated with caffeine consumption.

Caffeine in breast milk may potentially have a stimulating effect on breast fed infants.

Due to the caffeine content of this product it should not be used if you are pregnant or breast feeding.

4.7 Effects on ability to drive and use machines


4.8 Undesirable effects

Adverse events from historical clinical trial data are both infrequent and from small patient exposure. Accordingly, events reported from extensive post-marketing experience at therapeutic/labelled dose and considered attributable are tabulated below by MedDRA System Organ Class. Adverse reactions identified during post-marketing use are reported voluntarily from a population of uncertain size, the frequency of these reactions is unknown but likely to be very rare (<1/10,000).

Post marketing data


Body System

Undesirable effect

Blood and lymphatic system disorders



Immune system disorders

Very rare cases of serious skin reactions have been reported.


Cutaneous hypersensitivity reactions including (amongst others) skin rashes and angioedema.

Respiratory, thoracic and mediastinal disorders

Bronchospasm- more likely in patients sensitive to aspirin and other NSAIDs

Hepatobiliary disorders

Hepatic dysfunction


When the recommended paracetamol-caffeine dosing regimen is combined with dietary caffeine intake, the resulting higher dose of caffeine may increase the potential for caffeine-related adverse effects.

Body System

Undesirable effect

Central nervous system



Cardiac disorders


Psychiatric disorders



Anxiety and irritability

Gastrointestinal disorders

Gastrointestinal disturbances

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App store.

4.9 Overdose


Liver damage is possible in adults who have taken 10 g or more of paracetamol. Ingestion of 5 g or more of paracetamol may lead to liver damage if the patient has risk factors (see below).

Risk Factors:

If the patient

• Is on long term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St John's Wort or other drugs that induce liver enzymes.


• Regularly consumes ethanol in excess of recommended amounts.


• Is likely to be glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.


Symptoms of paracetamol overdose in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported.


Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of overdose or the risk of organ damage. Management should be in accordance with established treatment guidelines, see BNF overdose section.

Treatment with activated charcoal should be considered if the overdose has been taken within 1 hour. Plasma paracetamol concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable). Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of paracetamol, however, the maximum protective effect is obtained up to 8 hours post-ingestion. The effectiveness of the antidote declines sharply after this time. If required the patient should be given intravenous N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral methionine may be a suitable alternative for remote areas, outside hospital. Management of patients who present with serious hepatic dysfunction beyond 24h from ingestion should be discussed with the NPIS or a liver unit.



Overdose of caffeine may result in epigastric pain, vomitting, diuresis, tachycardia or cardia arrhythmia, CNS stimulation (insomnia, restlessness, excitement, agitation, jitteriness, tremors and convulsions).

It must be noted that for clinically significant symptoms of caffeine overdose to occur with this product, the amount ingested would be associated with serious paracetamol-related toxicity.


Patients should receive general supportive care (e.g. hydration and maintenance of vital signs). The administration of activated charcoal may be beneficial when performed within one hour of the overdose, but can be considered for up to four hours after the overdose. The CNS effects of overdose may be treated with intravenous sedatives.


Treatment of overdose with Cope Sachets requires assessment of plasma paracetamol levels for antidote treatment, with signs and symptoms of codeine and caffeine toxicity being managed symptomatically.

Sodium bicarbonate

High doses of sodium bicarbonate may be expected to induce gastrointestinal symptoms including belching and nausea. In addition, high doses of sodium bicarbonate may cause hypernatraemia; electrolytes should be monitored and patients managed accordingly.

5. Pharmacological properties
5.1 Pharmacodynamic properties

The combination of paracetamol and caffeine is a well established analgesic combination.

5.2 Pharmacokinetic properties

Paracetamol is rapidly and almost completely absorbed from the gastro-intestinal tract. It is relatively uniformly distributed throughout most body fluids and exhibits variable protein binding. Excretion is almost exclusively renal, in the form of conjugated metabolites.

Caffeine is absorbed readily after oral administration, maximal plasma concentrations are achieved within one hour and the plasma half-life is about 3.5 hours. 65 - 80% of administered caffeine is excreted in the urine as 1-methyluric acid and 1-methylxanthine.

5.3 Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

6. Pharmaceutical particulars
6.1 List of excipients

Sodium bicarbonate

Sorbitol powder

Saccharin sodium

Sodium lauryl sulphate

Citric acid (anhydrous)

Sodium carbonate (anhydous)


Dimeticone (Silicone Fluid 200/350)

Ph Eur

Ph Eur


Ph Eur

Ph Eur


Ph Eur

Ph Eur

6.2 Incompatibilities


6.3 Shelf life

48 months.

6.4 Special precautions for storage

The product should be stored below 30°C.

6.5 Nature and contents of container

Panadol Extra Soluble Tablets are foil-packed into either standard laminate strips comprising of 40 g/m2 paper/ 12 g/m2 polyethylene (PE)/ 8 µm or 12 µm Aluminium foil/ 23 g/m2 PE or child resistant laminate strips comprising of 19 µm polyethylene terephthalate (PET)/ 12 g/m2 PE/ 12 µm Aluminium foil/30 g/m2 PE.

The tablets are further packed into cardboard cartons.

These are available in packs of 4, 6, 12, 18, 24, 30, 48 or 60 soluble tablets.

6.6 Special precautions for disposal and other handling


7. Marketing authorisation holder

Haleon UK Trading Limited

The Heights



KT13 0NY

United Kingdom

8. Marketing authorisation number(s)

PL 44673/0077

9. Date of first authorisation/renewal of the authorisation

First Authorisation:

Last Renewal:



10. Date of revision of the text

6th September 2023

Haleon UK Trading Limited
Company image
The Heights, Weybridge, Surrey, KT13 0NY, UK
Medical Information Direct Line
0800 783 8881
Medical Information e-mail
[email protected]
Customer Care direct line
0800 783 8881